[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201402019TA - Overload and elute chromatography - Google Patents

Overload and elute chromatography

Info

Publication number
SG11201402019TA
SG11201402019TA SG11201402019TA SG11201402019TA SG11201402019TA SG 11201402019T A SG11201402019T A SG 11201402019TA SG 11201402019T A SG11201402019T A SG 11201402019TA SG 11201402019T A SG11201402019T A SG 11201402019TA SG 11201402019T A SG11201402019T A SG 11201402019TA
Authority
SG
Singapore
Prior art keywords
overload
elute chromatography
elute
chromatography
Prior art date
Application number
SG11201402019TA
Inventor
Deepa Nadarajah
Amit Mehta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201402019T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201402019TA publication Critical patent/SG11201402019TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/14—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the introduction of the feed to the apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201402019TA 2011-11-02 2012-11-02 Overload and elute chromatography SG11201402019TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554898P 2011-11-02 2011-11-02
PCT/US2012/063242 WO2013067301A1 (en) 2011-11-02 2012-11-02 Overload and elute chromatography

Publications (1)

Publication Number Publication Date
SG11201402019TA true SG11201402019TA (en) 2014-09-26

Family

ID=48192803

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402019TA SG11201402019TA (en) 2011-11-02 2012-11-02 Overload and elute chromatography

Country Status (26)

Country Link
US (3) US20140301977A1 (en)
EP (3) EP2773438B2 (en)
JP (4) JP6356607B2 (en)
KR (1) KR20140091721A (en)
CN (2) CN104023804B (en)
AU (1) AU2012323995B2 (en)
BR (1) BR112014010406A2 (en)
CA (1) CA2854330A1 (en)
DK (2) DK3257564T4 (en)
ES (2) ES2717536T3 (en)
FI (1) FI3257564T4 (en)
HK (1) HK1201489A1 (en)
HR (1) HRP20190485T4 (en)
HU (2) HUE035685T2 (en)
IL (1) IL232146A0 (en)
LT (1) LT3257564T (en)
MX (1) MX2014005330A (en)
PL (2) PL2773438T5 (en)
PT (1) PT3257564T (en)
RS (1) RS58472B2 (en)
RU (1) RU2014121884A (en)
SG (1) SG11201402019TA (en)
SI (2) SI2773438T2 (en)
TR (1) TR201903707T4 (en)
WO (1) WO2013067301A1 (en)
ZA (1) ZA201402932B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104722101A (en) 2010-07-30 2015-06-24 Emd密理博公司 Chromatography Media And Method
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20140091721A (en) 2011-11-02 2014-07-22 제넨테크, 인크. Overload and elute chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN105777862A (en) * 2012-10-24 2016-07-20 建新公司 Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SG10201804200WA (en) 2013-12-12 2018-07-30 Emd Millipore Corp Protein separations using an acrylamide containing filter
JP6603662B2 (en) * 2013-12-13 2019-11-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Protein thioether conjugation method
KR20150083689A (en) * 2014-01-10 2015-07-20 삼성전자주식회사 Method of Purification of anti-c-Met antibody
PL3116891T3 (en) 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
US10252258B2 (en) * 2014-03-24 2019-04-09 Nitto Boseki Co., Ltd. Method for separating and concentrating target substance using novel cationic graft polymer
JP2017519734A (en) * 2014-05-28 2017-07-20 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Virus reduction method
US10370408B2 (en) * 2014-06-25 2019-08-06 Jhl Biotech, Inc. Method for purification of a DNase or RNase protein from a sample
CN104208719B (en) * 2014-09-24 2017-05-03 北京天广实生物技术股份有限公司 ADC (antibody-drug conjugate) cation exchange chromatographic purification method
US20170298091A1 (en) * 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
SG10202005917SA (en) * 2015-03-06 2020-07-29 Genentech Inc Ultrapurified dsba and dsbc and methods of making and using the same
CN106290591B (en) * 2015-05-14 2019-07-26 上海医药工业研究院 A kind of detection method of Gentamicin C1a
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
JP7084301B2 (en) * 2015-08-21 2022-06-14 エフ．ホフマン－ラ ロシュ アーゲー Affinity chromatography purification method using low conductivity wash buffer
MX2019001572A (en) * 2016-08-15 2019-08-29 Genentech Inc Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide.
GB201702856D0 (en) * 2017-02-22 2017-04-05 Ge Healthcare Bio Sciences Ab Method in continuous chromatography
AU2018363202B2 (en) * 2017-11-08 2024-10-03 Blue Sky Vaccines Gmbh SO3 chromatography for use in a method for virus purification
EP3818150A1 (en) * 2018-07-04 2021-05-12 ProBioGen AG Method for purifying an enveloped virus
EP3899526B1 (en) * 2018-12-21 2024-05-01 Solventum Intellectual Properties Company Method for testing a chromatography device used for ion exchange
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
AR119264A1 (en) 2019-06-05 2021-12-09 Genentech Inc METHOD FOR REUSE OF CHROMATOGRAPHY
CN111351876A (en) * 2020-04-01 2020-06-30 上海中科新生命生物科技有限公司 Semi-absolute quantitative detection method for host cell protein in antibody drug
US11379651B1 (en) * 2020-07-06 2022-07-05 Turtl Surf & Immerse Limited Methods and systems for interactive content creation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
KR0149181B1 (en) 1990-06-29 1998-08-17 데이비드 알, 맥지 Melanin production by transformed microorganisms
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
ATE419355T1 (en) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
DE69333082T2 (en) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City OBTAINING HOMOZYGOTEM BY TARGETED GENETIC EVENTS
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
PT752248E (en) 1992-11-13 2001-01-31 Idec Pharma Corp THERAPEUTIC APPLICATION OF QUIMERIC ANTIBODIES AND RADIOACTIVELY MARKING OF ANTIGENES OF RESTRICTED DIFFERENTIATION OF HUMAN LYMPHOCYTE B FOR THE TREATMENT OF B-CELL LYMPHOMA
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
PT1538202E (en) * 1996-09-13 2014-04-22 Shire Human Genetic Therapies Production of human alpha-galactosidase a
ATE451391T1 (en) * 1996-11-27 2009-12-15 Genentech Inc AFFINITY PURIFICATION OF POLYPEPTIDE PROTEINS ON A MATRIX
EP1075488B2 (en) * 1998-05-06 2013-08-07 Genentech, Inc. Protein purification by ion exchange chromatography
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ES2376454T3 (en) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan EXPRESSION BOOKS IN FAGO OF VH HUMAN FRAGMENTS.
ATE365748T1 (en) * 2001-02-01 2007-07-15 Biogen Idec Inc POLYMER CONJUGATES OF NEUBLASTIN AND METHODS FOR THE USE THEREOF
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
US20070261962A1 (en) * 2002-04-02 2007-11-15 Ryszard Gajek Separation Systems with Charge Mosaic Membrane
AU2003301399B2 (en) * 2002-10-18 2006-07-06 Asahi Kasei Medical Co., Ltd. Microporous hydrophilic membrane
DE602004017726D1 (en) 2003-06-30 2008-12-24 Domantis Ltd Pegylated single-domain antibodies (dAb)
RU2367667C2 (en) 2004-08-19 2009-09-20 Дженентек, Инк. Polypeptide variants with changed effector function
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
BRPI0608584B8 (en) * 2005-03-11 2021-05-25 Wyeth Corp methods of recovering a purified product
WO2006116064A2 (en) 2005-04-22 2006-11-02 Waters Investments Limited Apparatus and methods for mass-spectrometric directed purification of biopolymers
BRPI0716382B8 (en) * 2006-08-28 2021-05-25 Ares Trading Sa method for reducing the content of free fc moieties in a fluid comprising an fc-containing protein, and use of cation exchange chromatography
NZ574623A (en) * 2006-08-28 2011-12-22 Ares Trading Sa Process for the purification of fc-fusion proteins
WO2008145351A1 (en) 2007-06-01 2008-12-04 F. Hoffmann-La Roche Ag Immunoglobulin purification
DE102009005479A1 (en) * 2009-01-21 2010-07-22 Sartorius Stedim Biotech Gmbh Apparatus and process for the separation of substances
JP5614936B2 (en) * 2009-02-19 2014-10-29 旭化成ケミカルズ株式会社 Method for purifying nucleic acid using porous membrane with immobilized anion exchange group
US8536316B2 (en) 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
WO2011035282A1 (en) 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
CN102094034A (en) * 2009-12-09 2011-06-15 泰州新生源生物医药有限公司 Process for purifying recombinant human Fc fusion pegylated interferon
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012068134A1 (en) 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
KR20140091721A (en) 2011-11-02 2014-07-22 제넨테크, 인크. Overload and elute chromatography

Also Published As

Publication number Publication date
DK2773438T4 (en) 2022-01-03
ES2637423T3 (en) 2017-10-13
JP6356607B2 (en) 2018-07-11
HUE035685T2 (en) 2018-05-28
US20140301977A1 (en) 2014-10-09
CN107163101A (en) 2017-09-15
CN104023804B (en) 2017-05-24
JP6979442B2 (en) 2021-12-15
HRP20190485T1 (en) 2019-04-19
SI3257564T1 (en) 2019-04-30
CA2854330A1 (en) 2013-05-10
LT3257564T (en) 2019-04-10
AU2012323995A1 (en) 2013-05-16
EP3257564B1 (en) 2019-01-23
EP2773438B2 (en) 2021-10-20
SI2773438T2 (en) 2022-05-31
US20210206836A1 (en) 2021-07-08
DK3257564T3 (en) 2019-04-15
PL3257564T5 (en) 2024-10-07
RS58472B2 (en) 2024-10-31
US20190023768A1 (en) 2019-01-24
EP2773438A4 (en) 2015-06-03
HRP20190485T4 (en) 2024-09-27
PL3257564T3 (en) 2019-06-28
JP2018184405A (en) 2018-11-22
CN107163101B (en) 2021-08-17
JP2022033774A (en) 2022-03-02
RU2014121884A (en) 2015-12-10
KR20140091721A (en) 2014-07-22
EP2773438B1 (en) 2017-06-14
DK2773438T3 (en) 2017-08-21
RS58472B1 (en) 2019-04-30
TR201903707T4 (en) 2019-04-22
EP3527274A1 (en) 2019-08-21
ZA201402932B (en) 2016-08-31
AU2012323995B2 (en) 2016-06-09
ES2717536T3 (en) 2019-06-21
NZ624317A (en) 2016-06-24
WO2013067301A1 (en) 2013-05-10
PT3257564T (en) 2019-03-22
EP3257564B2 (en) 2024-05-29
JP7203928B2 (en) 2023-01-13
JP2014532718A (en) 2014-12-08
PL2773438T5 (en) 2022-01-17
BR112014010406A2 (en) 2017-04-25
SI3257564T2 (en) 2024-10-30
DK3257564T4 (en) 2024-09-02
PL2773438T3 (en) 2017-11-30
ES2637423T5 (en) 2022-03-17
FI3257564T4 (en) 2024-08-30
CN104023804A (en) 2014-09-03
HUE043755T2 (en) 2019-09-30
SI2773438T1 (en) 2017-10-30
EP2773438A1 (en) 2014-09-10
JP2020059718A (en) 2020-04-16
MX2014005330A (en) 2014-09-08
EP3257564A1 (en) 2017-12-20
HK1201489A1 (en) 2015-09-04
IL232146A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
HK1201489A1 (en) Overload and elute chromatography
HUS2100012I1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
HK1211258A1 (en) Chromatographic materials
HK1205041A1 (en) Chromatography columns
EP2831096A4 (en) Affinity chromatography matrix
HK1214938A1 (en) Analytical aid
EP2780789A4 (en) Chromatography configuration interface
GB201020148D0 (en) Chromatography column
PL2691770T3 (en) Pre-concentrator
EP2590722A4 (en) Chromatography methods
GB201111775D0 (en) Compounds and uses thereof
GB2478652B (en) Chromatography assembly
AU346758S (en) Chromatography column
EP2803993A4 (en) Auto-sampler
GB201020146D0 (en) Chromatography column
GB201118317D0 (en) Intrathermic and interthermic extractive thermiats
AU346759S (en) Chromatography system
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof